| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
|
Purity: ≥98%
Salidroside (Rhodioloside) is a naturally occurring phenylpropanoid glycoside that has been isolated from Rhodiola rosea. It has been reported to have a wide range of pharmacological properties, including anticancer, antidepressant, and anxiolytic effects. Salidroside inhibits the growth of various human cancer cell lines in concentration- and time-dependent manners, and the sensitivity to salidroside is different in those cancer cell lines. Salidroside has been shown to inhibit CDK4, cyclin D1, cyclin B1, and Cdc2, while upregulating the levels of p27(Kip1) and p21(Cip1) and causing G1- or G2-phase arrest in various cancer cell lines. By triggering the ERK1/2 pathway and inhibiting caspase-3 activation, salidroside also reduces cell viability loss and apoptotic cell death brought on by H(2)O(2) stimulation in cultured NGF-differentiated PC12 cells.
| Targets |
mTOR
|
|---|---|
| ln Vitro |
Salidroside inhibits the growth of various human cancer cell lines in concentration- and time-dependent manners, and the sensitivity to salidroside is different in those cancer cell lines. Salidroside has been shown to inhibit CDK4, cyclin D1, cyclin B1, and Cdc2, while upregulating the levels of p27(Kip1) and p21(Cip1) and causing G1- or G2-phase arrest in various cancer cell lines. Salidroside also reduces the loss of cell viability and apoptotic cell death brought on by H(2)O(2) stimulation in cultured PC12 cells that have undergone NGF differentiation by activating the ERK1/2 pathway and inhibiting caspase-3 activation. [2] Salidroside induces PI3K/Akt pathway activation, which protects PC12 cells from MPP(+)-induced apoptosis and may be used to treat Parkinson's disease (PD).[3]
|
| ln Vivo |
Salidroside (20, 50, and 100 mg/kg) guards against oxidative stress caused by D-galactosamine and lipopolysaccharide in the liver tissue. [4]
|
| Cell Assay |
SH-SY5Y cells are seeded in 96-well plates at 1×104 cells per well. After the treatment with Salidroside (25-100 μM) and MPP+, cell viability is measured by MTT assay. Briefly, cells are incubated with 500 μg/mL MTT at 37°C for 4 h. The medium is then taken out, 150 L of DMSO is added, and shaking is carried out for 10 minutes. In a microplate reader, absorbance is measured at a wavelength of 570 nm, and the results are presented as folds of control.
|
| Animal Protocol |
Mice:
The 4-week-old male C57BL/6 mice are fed either a regular chow diet (n=8) or a high-fat diet (HFD) (n=16). Salidroside intervention (100 mg/kg/day) is started by gavage once a day for five weeks after the HFD has been administered for ten weeks. Vehicle (saline) is administered to the control groups. Male C57Bl/KsJ (BKS) mice that are 4 weeks old and BKS.Cg-Dock7m +/+ Leprdb/J (db/db) mice that are 16 weeks old are used. For five weeks, salidroside is administered orally by gavage at a dose of 100 mg/kg/day. Vehicle (saline) is administered to the control groups. Every five days, mice's body weight and fasting blood glucose levels are checked. Using a Glucometer, glucose readings are taken from blood drawn from the tail vein.
|
| References |
| Molecular Formula |
C14H20O7
|
|
|---|---|---|
| Molecular Weight |
300.3
|
|
| CAS # |
10338-51-9
|
|
| Related CAS # |
|
|
| Appearance |
Solid
|
|
| SMILES |
C1=CC(=CC=C1CCO[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)O
|
|
| InChi Key |
ILRCGYURZSFMEG-RKQHYHRCSA-N
|
|
| InChi Code |
InChI=1S/C14H20O7/c15-7-10-11(17)12(18)13(19)14(21-10)20-6-5-8-1-3-9(16)4-2-8/h1-4,10-19H,5-7H2/t10-,11-,12+,13-,14-/m1/s1
|
|
| Chemical Name |
(2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-[2-(4-hydroxyphenyl)ethoxy]oxane-3,4,5-triol
|
|
| Synonyms |
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (333.00 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3300 mL | 16.6500 mL | 33.3000 mL | |
| 5 mM | 0.6660 mL | 3.3300 mL | 6.6600 mL | |
| 10 mM | 0.3330 mL | 1.6650 mL | 3.3300 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Pdcd4 enhances cell sensitivity to OSI-906 via suppression of p70S6K1 phosphorylation.Mol Cancer Ther.2015 Mar;14(3):799-809. |
The combination of OSI-906 and PF-4708671 significantly inhibits the growth of resistant CRC cells.Mol Cancer Ther.2015 Mar;14(3):799-809. |
The combination of OSI-906 and PF-4708671 significantly inhibits the growth of HCT116-derived tumor in nude mice.Mol Cancer Ther.2015 Mar;14(3):799-809. |
Expression level of Pdcd4 correlates with cell sensitivity to OSI-906.Mol Cancer Ther.2015 Mar;14(3):799-809. |
Tumors derived from Pdcd4 knockdown cells resist to OSI-906 treatment.Mol Cancer Ther.2015 Mar;14(3):799-809. |
Knockdown of p70S6K1 but not p70S6K2 enhances cell sensitivity to OSI-906.Mol Cancer Ther.2015 Mar;14(3):799-809. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
